HC Surgical Specialists Limited Acquires 51% Stake in NYK Endoscopy and Digestive Centre Pte. Ltd. — Key Details and Investor Insights
Singapore, 8 June 2026 — HC Surgical Specialists Limited (“HCSS” or the “Company”) has made a strategic move by acquiring a 51% stake in NYK Endoscopy and Digestive Centre Pte. Ltd. (“NYKPL”) for a total consideration of S\$750,000. This acquisition marks a significant step in the company’s strategy to strengthen its position in the endoscopy and digestive health market in Singapore. Below, we break down the key highlights and implications for shareholders and potential investors.
1. Key Points of the Acquisition
- Acquisition Scope: HCSS has acquired 51% of NYKPL’s issued and paid-up share capital, making NYKPL a subsidiary of HCSS. The acquisition was completed on the same day as the signing of the sale and purchase agreement (“SPA”).
- Purchase Consideration: The S\$750,000 payment will be made in cash upon the commencement of Dr. Ng Yi Kang’s employment (expected around 1 July 2026).
- NYKPL Profile: NYKPL was incorporated on 2 June 2026 and has yet to commence operations. Its principal activity will be providing endoscopic procedures, complementing HCSS’s existing services.
- Synergy: The acquisition is expected to create synergy with HCSS’s general surgery and endoscopy services, supporting the group’s long-term growth strategy, particularly in view of Singapore’s ageing population.
- Management: Dr. Ng Yi Kang, an experienced gastroenterologist and hepatologist with over 15 years’ public hospital experience, will lead NYKPL. His expertise includes gut-brain disorders, GERD, diagnostic and therapeutic endoscopy, and advanced GI physiology testing.
2. Rationale and Strategic Importance
- The acquisition aligns with HCSS’s strategy to focus on endoscopic procedures, addressing increased demand due to Singapore’s ageing population.
- It is also aimed at cultivating young medical talent and expanding the company’s reach in digestive health services.
3. Financial Details and Shareholder Impact
- Book Value & NTA: NYKPL’s book value and net tangible asset value is S\$100, and it has no open market value as it has yet to start operations.
- Further Acquisition Option: HCSS has the option to acquire the remaining 49% of NYKPL by 30 November 2029. The price will be 11.4 times the highest unaudited profit after tax for any of the years ending 30 June 2027, 2028, or 2029 (after certain adjustments), multiplied by 0.49. The second consideration may be paid partly in HCSS shares.
- Put Options for HCSS: If Dr. Ng’s employment is terminated within the first 11 years, HCSS can require Dr. Ng to buy back its stake at a percentage of the original purchase or second consideration, depending on the timing of termination.
- Financial Effects: The acquisition is not expected to have a material impact on HCSS’s earnings per share (EPS) or net tangible assets (NTA) per share for the financial year ending 31 May 2027. The pro forma NTA per share would move from 11.45 cents to 10.96 cents, and EPS remains unchanged at 5.49 cents.
- Relative Figures: The transaction represents 1.34% of HCSS’s market capitalisation (S\$55.98 million), based on the volume weighted average price of S\$0.365 per share before the SPA, and is therefore considered a non-discloseable transaction under Catalist Rules.
4. Other Key Details for Shareholders
- No new directors will be appointed to the board as a result of this transaction.
- No existing directors or controlling shareholders have any direct or indirect interest in the acquisition, except through their shareholdings in HCSS.
- A copy of the SPA is available for inspection at HCSS’s registered office for three months from the date of announcement.
5. Potential Price Sensitive Developments
- The option to acquire the remaining 49% shares at a formula-based price, with payment potentially in shares, could be price sensitive in the future depending on NYKPL’s performance.
- Put options protect HCSS from downside risk if Dr. Ng’s employment ends prematurely.
- While the immediate financial impact is minimal, successful ramp-up of NYKPL’s operations under Dr. Ng’s leadership could be accretive in the long term.
- Announcements regarding the exercise of options for the remaining stake or any share issuance as consideration may materially affect share price when details are finalised.
6. About HC Surgical Specialists Limited
HCSS is a Singapore-listed medical services group with a network of 19 clinics, focused on endoscopic and colorectal procedures.
Disclaimer
This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research and consult professional advisers before making investment decisions. The information contained herein is based on public disclosures by HC Surgical Specialists Limited as of 8 June 2026.
华语版
HC Surgical Specialists Limited 收购 NYK 内窥镜与消化中心 51% 股权 —— 投资者详细解读
新加坡，2026年6月8日 —— HC Surgical Specialists Limited（“HCSS”或“公司”）宣布以75万新元收购 NYK Endoscopy and Digestive Centre Pte. Ltd.（“NYKPL”）51% 的已发行股本。本次收购标志着公司在新加坡内窥镜及消化健康市场的又一重要布局。以下为投资者带来详细分析：
1. 收购要点
- 收购范围：HCSS已收购NYKPL 51%股权，使NYKPL成为其子公司，收购协议当日即完成交割。
- 对价：75万新元将于Dr. Ng Yi Kang（黄医康医生）入职后全额支付（预计2026年7月1日左右）。
- NYKPL简介：NYKPL于2026年6月2日注册成立，尚未开展业务，未来主营内窥镜检查服务，补充HCSS现有业务。
- 协同效应：收购将与HCSS普通外科及内窥镜服务形成协同，支持集团长期增长战略，特别是应对新加坡老龄化趋势。
- 管理层：由拥有15年公立医院经验的胃肠肝病专家 Dr. Ng 领导，专长包括肠脑互动障碍、胃食管反流病、诊断和治疗性内窥镜及高级生理测试。
2. 战略意义
- 本次收购契合HCSS聚焦内窥镜服务的战略，响应新加坡老龄化带来的消化健康需求增长。
- 也有助于吸引和培养年轻医生，扩大公司在消化健康领域的影响力。
3. 财务细节与股东影响
- 账面价值与净有形资产：NYKPL账面价值及净有形资产为100新元，尚未开展业务，无公开市场估值。
- 追加收购选项：HCSS有权在2029年11月30日前，以一定公式收购剩余49%股份，对价为NYKPL 2027、2028或2029年中利润最高一年的税后利润的11.4倍（经特定调整后）再乘以0.49，部分可用公司股票支付。
- 回购权利：若Dr. Ng在11年内离职，HCSS可要求其按一定比例现金回购股份，对价与原始/第二次收购价相关，比例视离职时点而定。
- 财务影响：收购预计不会对截至2027年5月31日止财年EPS或NTA产生重大影响。模拟NTA每股由11.45新分降至10.96新分，EPS维持5.49新分。
- 相对比例：本次交易占公司市值1.34%（市值为5598万新元，SPA前成交均价0.365新元/股），为非须披露交易。
4. 股东需关注事项
- 收购后不会有新董事加入董事会。
- 公司现有董事及控股股东除持股外，无其他利益关系。
- SPA可于公告后三个月内于公司注册办事处查阅。
5. 可能影响股价的发展
- 未来如行使追加收购权并部分以股票支付，或将对公司估值产生影响，相关公告将属敏感信息。
- 回购权安排为HCSS提供保障，降低管理层变动风险。
- 虽然短期财务影响有限，但若NYKPL在Dr. Ng领导下快速成长，长期有望提升业绩及市值。
- 关于追加收购或发行新股的任何新公告，均有可能对股价产生实质性影响。
6. 公司简介
HCSS是新加坡上市医疗服务集团，旗下拥有19家诊所，专注于内窥镜及结直肠手术。
免责声明
本文仅供参考，不代表任何投资建议。投资者应自行研究并咨询专业人士再做决定。信息基于HCSS 2026年6月8日公开披露内容。
